16.1
传统口服制剂称为速释制剂(IR),其设计目的是在口服后迅速释放活性药物成分(API),通常为片剂或胶囊剂。这种快速释放通常会使药物迅速吸收并产生相应的药效学作用,但起效时间及效应强度会因药物性质而异。这些制剂中的前药需要经代谢转化后方能发挥药效学作用,因此起效会有所延迟。同样,难溶性(脂溶性)药物由…
传统的速释制剂在服用后立即释放活性成分,导致快速吸收。然而,含有难溶性药物的制剂可能表现出较慢的吸收速度。
为了克服这些局限性,已设计出缓释制剂以控制药物释放模式。目前已有多种类型的口服缓释药物产品。
缓释制剂旨在持续释放药物,维持较长时间的治疗浓度,并减少给药频率。
缓释制剂通常带有肠溶包衣,可保护药物免受胃部酸性环境的影响,并确保药物仅在肠道中释放,从而优化吸收特征。
靶向释放制剂可将药物递送至特定的体内部位,从而最大化治疗效果并最小化全身暴露。这些制剂可设计为实现药物的即时释放或持续释放。
口服崩解片可在唾液中迅速溶解,实现药物的直接颊部吸收并更快地发挥治疗作用。
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between immediate-release and modified-release drug formulations?
Immediate-release formulations release the active pharmaceutical ingredient promptly upon ingestion, leading to rapid absorption and quick therapeutic effects. Modified-release formulations deliberately alter drug release rate and timing to achieve specific therapeutic goals, maintain consistent drug levels, and improve patient adherence by reducing dosing frequency.
Q2: How do extended-release formulations maintain therapeutic drug levels?
Extended-release formulations utilize advanced technologies such as matrix systems and osmotic pumps to control drug release gradually over extended periods. Matrix systems embed the drug in a dissolving matrix, while osmotic pumps release drug through a semipermeable membrane opening, maintaining steady bloodstream levels and minimizing fluctuations.
Q3: Why are enteric coatings used in delayed-release formulations?
Enteric coatings protect drugs from the acidic stomach environment by resisting stomach acid and ensuring release only in the intestines. This approach optimizes absorption profiles and reduces gastric irritation, exemplified by enteric-coated aspirin, which enhances therapeutic efficacy while mitigating side effects.
Q4: What are the advantages of targeted-release drug delivery systems?
Targeted-release formulations deliver drugs directly to specific physiological sites using advanced carriers like liposomes or nanoparticles, enhancing therapeutic effects while minimizing systemic exposure. This precise delivery and localized action is particularly beneficial in treatments like cancer therapy, reducing unwanted side effects.
Q5: How do orally disintegrating tablets benefit patients with swallowing difficulties?
Orally disintegrating tablets dissolve rapidly in saliva, facilitating quick drug absorption without requiring water. This formulation enables direct buccal drug absorption and quicker therapeutic effects, making them particularly suitable for patients with swallowing difficulties or those unable to take conventional tablets.
Q6: What factors affect drug absorption in immediate-release formulations?
Drug absorption in immediate-release formulations depends on the drug's physicochemical properties. Poorly soluble drugs may exhibit slower absorption due to gradual dissolution in the gastrointestinal tract, while prodrugs require metabolic conversion to activate their effects, introducing delays in onset times.
Q7: How do modified-release formulations improve patient adherence?
Modified-release formulations reduce dosing frequency by maintaining therapeutic drug levels over extended periods, allowing patients to take medication less often. This consistent drug delivery minimizes fluctuations in blood concentration, improving treatment outcomes and making medication regimens easier for patients to follow.